Marshall Wace
INSY

Marshall Wace’s Insys Therapeutics, Inc. INSY Stock Holding History

Marshall Wace’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-13,726
Closed -$266K – 1054
2014
Q3 		$266K Buy
+13,726
New +$216K ﹤0.01% 727

Other funds holding INSY

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Marshall Wace's INSY Position: Q4 2014 in Review

Marshall Wace sold out of Insys Therapeutics, Inc. (INSY) in Q4 2014, closing a stake of 13,726 shares — an estimated $266K sold.

Marshall Wace first reported a position in INSY in Q3 2014 and held it in 1 quarter. The position peaked at $266K in Q3 2014. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2014.

  • Marshall Wace reported no remaining Insys Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • Marshall Wace sold 13,726 Insys Therapeutics, Inc. shares in Q4 2014, an estimated $266K.
  • Marshall Wace first reported a position in Insys Therapeutics, Inc. in Q3 2014 and held it in 1 quarter.
  • Marshall Wace's Insys Therapeutics, Inc. position peaked at $266K in Q3 2014.
  • 113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2014.

Based on Marshall Wace's 13F filing for Q4 2014, filed 17 Feb 2015.